Sanofi

COVID-19 vaccine approval unlikely before November, says US NIH director

This includes potential vaccines from Johnson &Johnson, AstraZeneca/Oxford University, Pfizer/BioNTech, GlaxoSmithKline/Sanofi, Moderna and Novavax.

US pays $1.5bn for 100 million doses of Moderna’s COVID-19 vaccine

The US has already secured doses from a host of drugmakers currently developing COVID-19 vaccines, including Johnson &Johnson, Pfizer/BioNTech, Sanofi/GlaxoSmithKline and Novavax.

Novartis builds its case for novel MS treatment ofatumumab

The ASCLEPIOS I and II trials evaluated a subcutaneous injection of ofatumumab compared to Sanofi’s once-daily oral Aubagio (teriflunomide) pill in adults with relapsing multiple sclerosis (RMS). ... This included a 51% and 58% reduction in ARR

J&J inks $1bn deal with US for coronavirus vaccine

This includes a deal with Sanofi/GlaxoSmithKline for 100 million doses, as well as a $1.95bn deal for 100 million doses of Pfizer/BioNTech’s candidate and similar deals with

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

In 2019, French drugmaker Sanofi also scaled back on a gene therapy alliance with Voyager for a second time. ... Neurocrine picked up rights to the programme after Sanofi gave them up back in 2017.

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]